Carisma Therapeutics Inc (NASDAQ: CARM) on Tuesday, soared 2.50% from the previous trading day, before settling in for the closing price of $0.26. Within the past 52 weeks, CARM’s price has moved between $0.14 and $1.27.
A company in the Healthcare sector has jumped its sales by 42.71% annually for the last half of the decade. The company achieved an average annual earnings per share of 52.74%. With a float of $24.89 million, this company’s outstanding shares have now reached $41.79 million.
Carisma Therapeutics Inc (CARM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Carisma Therapeutics Inc is 40.44%, while institutional ownership is 4.28%. The most recent insider transaction that took place on Oct 07 ’25, was worth 14,183. Before that another transaction happened on Oct 02 ’25, when Company’s Chief Scientific Officer sold 200,000 for $0.25, making the entire transaction worth $50,860. This insider now owns 119,347 shares in total.
Carisma Therapeutics Inc (CARM) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.31 earnings per share (EPS) for the period topping the consensus outlook (set at -0.36) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.95% during the next five years compared to 42.71% growth over the previous five years of trading.
Carisma Therapeutics Inc (NASDAQ: CARM) Trading Performance Indicators
Carisma Therapeutics Inc (CARM) is currently performing well based on its current performance indicators. A quick ratio of 0.48 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Carisma Therapeutics Inc (CARM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.42 million. That was inferior than the volume of 7.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 32.02%.
During the past 100 days, Carisma Therapeutics Inc’s (CARM) raw stochastic average was set at 10.70%, which indicates a significant decrease from 24.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0295 in the past 14 days, which was lower than the 0.0467 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2973, while its 200-day Moving Average is $0.3475. However, in the short run, Carisma Therapeutics Inc’s stock first resistance to watch stands at $0.2699. Second resistance stands at $0.2775. The third major resistance level sits at $0.2899. If the price goes on to break the first support level at $0.2499, it is likely to go to the next support level at $0.2375. The third support level lies at $0.2299 if the price breaches the second support level.
Carisma Therapeutics Inc (NASDAQ: CARM) Key Stats
Market capitalization of the company is 10.97 million based on 41,788K outstanding shares. Right now, sales total 19,630 K and income totals -60,480 K. The company made 3,730 K in profit during its latest quarter, and -9,270 K in sales during its previous quarter.
